United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals

Iovance Biotherapeutics

Could the second half of the year be as much fun as the first?

These 3 Biotech Stocks Doubled in the First Half of 2019

AbbVie

Editas Medicine

They might be this year's Bad News Bears, but I think these three stocks will be long-term winners.

Why I'm Sticking With My 3 Worst-Performing Stocks of 2019 So Far

Array BioPharma (ARRY) reported earnings 30 days ago. What's next for the stock?

Why Is Array BioPharma (ARRY) Up 27.1% Since Last Earnings Report?

America's largest pharmaceutical company had plenty of good reasons not to pursue a potential new Alzheimer's treatment.

5 Reasons Pfizer Sat on a Potential New Alzheimer's Drug

Walmart

FleetCor Technologies

The stock charts of WMT, FLT and PFE are headed into the latter half of the week at inflection points. Here's what you can expect from each.

3 Big Stock Charts for Thursday: Pfizer, Walmart and FleetCor Technologies

Pfizer is fighting back against a report that it hid the potential of a blockbuster drug to prevent Alzheimer’s disease in order to avoid shelling out for a “costly clinical trial.” Researchers at Pfizer in 2015 found that Enbrel, an anti-inflammatory drug used to treat rheumatioid arthritis, seemed to reduce the risk of Alzheimer’s disease.

Pfizer denies report it hid possible Alzheimer’s breakthrough

Pfizer (PFE) looks well positioned to launch several breakthrough innovative medicines in the next five years amid loss of exclusivity headwinds.

Pfizer to Launch Several Drugs Despite Generic Headwinds

Johnson & Johnson

Verizon

Many of the stocks in the Dow Industrial Average dropped sharply in May as fears over the deepening trade war made them less attractive to investors. In his regular monthly scan, Viper Report’s Tom Aspray discusses the four most oversold Dow stocks.

The Four Most Oversold Dow Stocks

Avalara Inc

Guardant Health Inc

Mirati Therapeutics

Spark Therapeutics

Roku

Sinclair Inc

Snap

Roku, Array Biopharma and Guardant Health are just some of the best stocks by returns for the first half of 2019. The post The 10 Best Stocks for 2019 — So Far appeared first on InvestorPlace.

The 10 Best Stocks for 2019 — So Far

Coca-Cola

NIKE

VMware

Top Research Reports for Pfizer, Coca-Cola & VMware

Amgen

Gilead Sciences

Success with an experimental new oncology treatment that scratches a 35-year itch is good news for more than one biotech stock.

3 Cancer Stocks Given a Lift by Amgen

Chevron

AT&T

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Exxon Mobil

According to the GuruFocus All-in-One Screener, the following companies have high dividend yields but performed poorly over the last 12 months.

6 High-Yield Stocks

Cisco Systems

JPMorgan Chase & Co

The eight “Dogs of the Dow” for 2019 have an aggregate year-to-date gain of 5.5% at the end of May, down from 12.2% at the end of April. Here's how to buy and sell them now.

'Dogs Of The Dow' Slump, Here's How To Trade Them Now

McDonald's

Merck

Travelers

UnitedHealth Group

Just five Dow components were poised for May gains Thursday afternoon, a reflection of the effect the trade war is having on Wall Street.

Only five Dow stocks have gained in May as trade war drags on

Amicus Therapeutics

Amicus Therapeutics and Array BioPharma are two top growth stocks to consider buying now.

2 Ultra-High-Growth Biotech Stocks to Buy Now

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?

Pfizer (PFE) Up 2.3% Since Last Earnings Report: Can It Continue?

Array obtained positive results for its phase 3 BEACON CRC study using BRAFTOVI, METKOVI, and ERBITUX to treat patients with BRAF mutant metastatic colorectal cancer.

Array's Positive Phase 3 Results Make The Case For Revenue Growth For BRAFTOVI And METKOVI

Bristol-Myers

Eli Lilly

And the analyst really likes one in particular.

This Just In: Goldman Sachs Picks 4 Big Pharma Stocks to Buy

Boston Scientific

U.S. equities are mostly higher in post-holiday trading on Tuesday, as investors are looking for stocks to buy.

4 Drug and Health Stocks Pushing Higher  

Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.

Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study

Pfizer Inc. said late Friday one of its drugs did not meet set goals for the treatment of epilepsy in a late stage clinical trial.

Pfizer's Lyrica doesn't meet endpoint in epilepsy study

10-year chart shows strong support for shares.

Pfizer Has Limited Downside

News for Pfizer Stock (PFE)